Novartis will not pursue Kymriah’s use in second-line lymphoma; but have Breyanzi and Yescarta proved enough to be filed in this setting?
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
Gilead opts in at long last, and that’s more than many might have been expecting.
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.